Before revision:  These results highlight the urgent need for prospective trials testing whether prophylactic use of \alpha_1-AR antagonists ameliorates diseases associated with cytokine storm syndrome, such as COVID-19.
After revision:  These results highlight the urgent need for prospective trials testing whether prophylactic use of \alpha_1-AR antagonists ameliorates lower respiratory tract infection-associated cytokine storm syndrome, such as COVID-19.